Veracyte(US:VCYT) ZACKS·2025-12-02 15:52Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks likely to outperform the market in the next 30 days [2][3] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - The Growth Style Score assesses a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score evaluates stocks based on price trends and earnings estimate changes, aiding investors in timing their purchases [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking attractive value, growth, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.93% since 1988 [7][10] - Stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended for the highest probability of success [9] Company Spotlight: Veracyte (VCYT) - Veracyte is a diagnostics company specializing in cancer detection, offering advanced genomic tests for various cancers [11] - VCYT holds a 1 (Strong Buy) Zacks Rank and a VGM Score of B, with a Growth Style Score of B indicating a projected year-over-year earnings growth of 38.7% for the current fiscal year [12] - The Zacks Consensus Estimate for VCYT's earnings has increased by $0.23 to $1.65 per share, with an average earnings surprise of +45.1% [12][13]